

Study of daclizumab yields mixed results in multiple sclerosis

October 8 2015



(HealthDay)—Multiple sclerosis patients taking daclizumab high yield process (HYP), a humanized monoclonal antibody that binds to CD25 (alpha subunit of the interleukin-2 receptor) and modulates interleukin-2 signaling, experienced lower relapse rates but more side effects than patients receiving interferon beta-1a, new research indicates. The study was published in the Oct. 8 issue of the *New England Journal of Medicine*.

In the new study, led by scientists at University Hospital Basel in Switzerland, 1,841 patients with relapsing-remitting multiple sclerosis were randomly assigned to receive either daclizumab HYP or [interferon beta-1a](#) over a period averaging about two years.

While daclizumab recipients experienced much lower relapse rates than those on interferon beta-1a, disability progression 12 weeks after the study's start was similar in both groups—16 percent with daclizumab and 20 percent with interferon beta-1a. But side effects, including serious infections and cutaneous events such as rash or eczema, were far more common among daclizumab recipients.

"Among [patients](#) with relapsing-remitting multiple [sclerosis](#), daclizumab HYP showed efficacy superior to that of interferon beta-1a with regard to the annualized relapse rate and lesions, as assessed by means of [magnetic resonance imaging](#), but was not associated with a significantly lower risk of disability progression confirmed at 12 weeks," the authors conclude. "The rates of infection, rash, and abnormalities on liver-function testing were higher with daclizumab HYP than with interferon beta-1a."

The study was funded by Biogen and AbbVie Biotherapeutics, the manufacturers of daclizumab.

More information: [Full Text \(subscription or payment may be required\)](#)

Copyright © 2015 [HealthDay](#). All rights reserved.

Citation: Study of daclizumab yields mixed results in multiple sclerosis (2015, October 8) retrieved 25 April 2024 from <https://medicalxpress.com/news/2015-10-daclizumab-yields-results-multiple-sclerosis.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--